Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography

TIPRE00015147 | Pages: 133 | Biotechnology | Oct 2020 | Type: Regional | Status: Published

Market Introduction

RNA interference (RNAi) is a vital biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. RNAi is an essential research tool in cell culture and living organisms because synthetic dsRNA introduced into cells can induce the suppression of specific genes of interest. RNAi may be used for large-scale screens that orderly shutdown each gene in the cell, which can help to know the components necessary for a particular cellular event such as cell division. The pathway is also used as a practical tool in medicine, biotechnology, and insecticides.


Get more information on this report :



Market Overview and Dynamics

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is anticipated to grow at a CAGR of 9.3% during 2019–2027. The growth of the market is attributed to factors such as growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions. However, high cost of RNAi therapy development is expected to restrain the growth of the market to a certain extent during the forecast period.

Key Market Segments

In terms of molecule type, the small interfering RNAs (siRNA) segment accounted for larger share of the Asia Pacific RNAi therapeutics market in 2019. Based on route of administration, the pulmonary delivery segment held the largest share of the Asia Pacific RNAi therapeutics market in 2019. In terms of application, the oncology segment accounted for the largest share of the market in 2019. Based on end user, the research and academic laboratories segment held the largest share of the Asia Pacific RNAi therapeutics market in 2019.

Major Sources and Companies Listed

Major primary and secondary sources associated with the Asia Pacific RNAi therapeutics market report are the World Health Organization (WHO), Chinese Center for Disease Control and Prevention, and World Population Prospects, among others.

 

 

Reasons to buy report

  • It provides understanding of the Asia Pacific RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return
  • It guides to stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific RNAi therapeutics market
  • It helps efficiently plan merger and acquisition and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
  • It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of various segments pertaining to the Asia Pacific RNAi therapeutics market.
  • It provides revenue forecast of the market based on various segments for the period from 2019 to 2027

ASIA PACIFIC RNAI THERAPEUTICS MARKET SEGMENTATION

By Molecule Type

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

 

By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others

 

By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others

 

 

By End User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories

 

By Country

  • Japan
  • China
  • India
  • South Korea
  • Australia

 

Company Profiles

  • Benitec Biopharma
  • Olix Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.

 

 

 

1.          Introduction

1.1        Scope of the Study

1.2        The Insight Partners Research Report Guidance

1.3        Market Segmentation

1.3.1        Asia Pacific RNAi Therapeutics Market – By Molecule Type

1.3.2        Asia Pacific RNAi Therapeutics Market – By Application

1.3.3        Asia Pacific RNAi Therapeutics Market – By Route of Administration

1.3.4        Asia Pacific RNAi Therapeutics Market– By End User

1.3.5        Asia Pacific RNAi Therapeutics Market – By Country

2.          Asia Pacific RNAi Therapeutics Market – Key Takeaways

3.          Research Methodology

3.1        Coverage

3.2        Secondary Research

3.3        Primary Research

4.          Asia Pacific RNAi Therapeutics Market – Market Landscape

4.1        Overview

4.2        PEST Analysis

4.2.1        RNAi therapeutics Market - Asia Pacific PEST Analysis

4.3        Expert Opinion

5.          Asia Pacific RNAi Therapeutics Market - Key Market Dynamics

5.1        Key Market Drivers

5.1.1        Growing Investments in RNAi Therapies

5.1.2        Rising Prevalence of Chronic Conditions and Infectious Diseases

5.2        Market Restraints

5.2.1        High Cost for RNAi Therapy Development

5.3        Market Opportunities

5.3.1        Significant Number of Pipeline Candidates for Strategic Alliances

5.4        Future Trends

5.4.1        Rising Emphasis on RNA Technologies

5.5        Impact analysis

6.          RNAi Therapeutics Market – Asia Pacific Analysis

6.1        Asia Pacific RNAi Therapeutics Market Revenue Forecasts and Analysis

7.          Asia Pacific RNAi Therapeutics Market Analysis and Forecasts To 2027 – By Molecule Type

7.1        Overview

7.2        Asia Pacific RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

7.2.1        Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)

7.3        Small Interfering RNAs (siRNA)

7.3.1        Overview

7.3.2        Asia Pacific Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)

7.4        MicroRNA (miRNA)

7.4.1        Overview

7.4.2        Asia Pacific MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

8.          Asia Pacific RNAi therapeutics Market Analysis and Forecasts To 2027 – By Application

8.1        Overview

8.2        Asia Pacific RNAi therapeutics Market, By Application 2019 & 2027 (%)

8.2.1        Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)

8.3        Genetic Disorders

8.3.1        Overview

8.3.2        Asia Pacific Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)

8.4        Oncology

8.4.1        Overview

8.4.2        Asia Pacific Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

8.5        Neurodegenerative Disorders

8.5.1        Overview

8.5.2        Asia Pacific Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.6        Cardiovascular Disorders

8.6.1        Overview

8.6.2        Asia Pacific Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.7        Respiratory Disorders

8.7.1        Overview

8.7.2        Asia Pacific Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.8        Infectious Diseases

8.8.1        Overview

8.8.2        Asia Pacific Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.9        Renal Diseases

8.9.1        Overview

8.9.2        Asia Pacific Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.10      Other Disorders

8.10.1     Overview

8.10.2     Asia Pacific Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

9.          Asia Pacific RNAi therapeutics Market Analysis and Forecasts To 2027 – By Route of Administration

9.1        Overview

9.2        Asia Pacific RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

9.2.1        Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

9.3        Intradermal Injections

9.3.1        Overview

9.3.2        Asia Pacific Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)

9.4        Pulmonary Delivery

9.4.1        Overview

9.4.2        Asia Pacific Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

9.5        Intravenous Injections

9.5.1        Overview

9.5.2        Asia Pacific Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.6        Intraperitoneal Injections

9.6.1        Overview

9.6.2        Asia Pacific Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.7        Other Route of Administrations

9.7.1        Overview

9.7.2        Asia Pacific Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

10.       Asia Pacific RNAi Therapeutics Market Analysis – By End-User

10.1      Overview

10.2      Asia Pacific RNAi Therapeutics Market, By End-User 2019-2027 (%)

10.2.1     Asia Pacific RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)

10.3      Diagnostic Laboratories

10.3.1     Overview

10.3.2     Asia Pacific Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.4      Research and Academic Laboratories

10.4.1     Overview

10.4.2     Asia Pacific Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.5      Hospitals

10.5.1     Overview

10.5.2     Asia Pacific Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

11.       RNAi therapeutics Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1      Asia Pacific: RNAi Therapeutics Market

11.1.1     Overview

11.1.2     Asia Pacific: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11.1.3     Asia Pacific: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.4     Asia Pacific: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.5     Asia Pacific: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.6     Asia Pacific: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.7     Asia Pacific: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

11.1.8     China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1       China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2       China: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.8.3       China: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.8.4       China RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.8.5       China RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.9     Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1       Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2       Japan: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.9.3       Japan: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.9.4       Japan RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.9.5       Japan RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.10   India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1    India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2    India: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.10.3    India: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.10.4    India RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.10.5    India RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.11   South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.1    South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.2    South Korea: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.11.3    South Korea: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.11.4    South Korea RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.11.5    South Korea RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.12   Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.1    Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.2    Australia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.12.3    Australia: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.12.4    Australia RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.12.5    Australia RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

12.       Impact of COVID-19 Pandemic on Asia Pacific RNAi therapeutics Market

12.1      Asia Pacific: Impact Assessment of COVID-19 Pandemic

13.       Company Profiles

13.1      Benitec Biopharma

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Olix Pharmaceuticals, Inc.

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      GlaxoSmithKline plc.

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Alnylam Pharmaceuticals, Inc.

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Arrowhead Pharmaceuticals, Inc

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

14.       Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.            Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)

Table 2.            Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 3.            Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 4.            Asia Pacific RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)

Table 5.            Asia Pacific RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)

Table 6.            Asia Pacific RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 7.            Asia Pacific RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 8.            Asia Pacific RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 9.            China RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 10.          China RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.          China RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12.          China RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 13.          Japan RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 14.          Japan RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 15.          Japan RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 16.          Japan RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 17.          India RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 18.          India RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 19.          India RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 20.          India RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 21.          South Korea RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 22.          South Korea RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 23.          South Korea RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 24.          South Korea RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 25.          Incidence, Mortality and Prevalence by cancer site, Australia, 2018

Table 26.          Australia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 27.          Australia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 28.          Australia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 29.          Australia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 30.          Glossary of Terms, RNAi Therapeutics Market

 

LIST OF FIGURES

Figure 1.           RNAi Therapeutics Market Segmentation

Figure 2.           Asia Pacific RNAi Therapeutics Market Overview

Figure 3.           Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market

Figure 4.           China is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           Asia Pacific RNAi Therapeutics Market - Leading Country Markets (US$ Mn)

Figure 6.           RNAi Therapeutics Market - Asia Pacific PEST Analysis

Figure 7.           RNAi Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8.           Asia Pacific RNAi Therapeutics Market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9.           Asia Pacific RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

Figure 10.        Asia Pacific Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        Asia Pacific MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Asia Pacific RNAi therapeutics Market, By Application 2019 & 2027 (%)

Figure 13.        Asia Pacific Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Asia Pacific Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Asia Pacific Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Asia Pacific Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        Asia Pacific Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        Asia Pacific Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        Asia Pacific Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        Asia Pacific Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.        Asia Pacific RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

Figure 22.        Asia Pacific Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        Asia Pacific Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24.        Asia Pacific Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        Asia Pacific Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26.        Asia Pacific Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 27.        Asia Pacific RNAi Therapeutics Market, by End-User 2019 & 2027 (%)

Figure 28.        Asia Pacific Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29.        Asia Pacific Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)

Figure 30.        Asia Pacific Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 31.        Asia Pacific: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 32.        Asia Pacific RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 33.        China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 34.        Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 35.        India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 37.        Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 38.        Impact of COVID-19 Pandemic in Asia-Pacific Country Markets

 

  1. Benitec Biopharma
  2. Olix Pharmaceuticals, Inc.
  3. GlaxoSmithKline plc
  4. Alnylam Pharmaceuticals, Inc.
  5. Arrowhead Pharmaceuticals, Inc
  • It provides understanding of the Asia Pacific RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return
  • It guides to stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific RNAi therapeutics market
  • It helps efficiently plan merger and acquisition and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
  • It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of various segments pertaining to the Asia Pacific RNAi therapeutics market.
  • It provides revenue forecast of the market based on various segments for the period from 2019 to 2027
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
$1800
Site License
$4000
$2400
Enterprise License
$5000
$3000